GlassScriptPhysician profile
Sonam Rama
NPI 1174915532
$71,581.14
in general payments reported to CMS, 2019-2025
35 companies · $28K in 2025
The $28K reported for 2025 was more than what 95% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,544 · 2020: $590 · 2021: $1,208 · 2022: $1,682 · 2023: $4,366 · 2024: $34K · 2025: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $41K · Consulting Fee: $10K · Food and Beverage: $8,569 · Travel and Lodging: $6,444 · Education: $356.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $41,143.00 |
| Consulting Fee | $10,045.00 |
| Food and Beverage | $8,568.88 |
| Travel and Lodging | $6,444.49 |
| Education | $355.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $59,754.84 | 2022-2025 | Sotyktu |
| Abbvie INC. | $1,827.85 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,342.56 | 2019-2025 | |
| Janssen Biotech, INC. | $1,293.99 | 2020-2025 | Tremfya |
| Genzyme Corporation | $979.40 | 2019-2025 | |
| Lilly USA, LLC | $723.96 | 2020-2025 | Taltz, Olumiant, Ebglyss |
| Amgen INC. | $698.40 | 2019-2025 | Otezla |
| Pfizer INC. | $691.38 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $650.27 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| Galderma Laboratories, L.P. | $616.98 | 2020-2025 | Nemluvio, Aklief |
| Ucb, INC. | $582.30 | 2019-2025 | Bimzelx, Cimzia |
| Arcutis Biotherapeutics, INC. | $387.35 | 2023-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $342.05 | 2020-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $329.63 | 2022-2025 | Adbry |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $223.81 | 2019-2025 | Jublia, Siliq, Cabtreo |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $158.29 | 2022-2025 | Opzelura |
| Paratek Pharmaceuticals, INC. | $125.64 | 2024-2025 | Nuzyra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.91 | 2023-2025 | Spevigo, Cyltezo |
| Organogenesis INC. | $100.68 | 2023 | Puraply |
| Biofrontera INC. | $88.69 | 2021-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Sanofi-Aventis U.S. LLC | $79.99 | 2021 | |
| Dermavant Sciences, INC. | $78.41 | 2023-2024 | Vtama |
| Genentech USA, INC. | $52.86 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $50.18 | 2023-2024 | Tremfya |
| Regeneron Pharmaceuticals, INC. | $45.00 | 2019 | |
| Celgene Corporation | $44.59 | 2019 | |
| Kerecis Limited | $33.24 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Almirall LLC | $22.91 | 2021 | |
| Supernus Pharmaceuticals, INC. | $22.84 | 2022 | |
| Botanix Sb INC | $19.67 | 2025 | Sofdra |
| Organon LLC | $18.94 | 2025 | |
| Krystal Biotech INC | $18.90 | 2025 | Vyjuvek |
| Dermira, INC. | $17.75 | 2020 | |
| Smith+Nephew, INC. | $17.66 | 2019 | |
| Allergan, INC. | $15.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonam Rama listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.